| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:01 | XFRA NEW INSTRUMENTS AVAILABLE ON 05.10.2026 | 163 | Xetra Newsboard | The following instruments on XETRA do have their first trading 05.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 05.10.2026
Aktien
1 US16934F1030 Chilwa Minerals Ltd.... ► Artikel lesen | |
| Fr | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | 1.501 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| Fr | XFRA ISIN CHANGE | 519 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenSE0018538068 Verve Group Media SE 02.10.2026 IE000ZVY0237 Verve Group Media SE 05.10.2026 Tausch 1:1 CA86332K4000 Strikepoint... ► Artikel lesen | |
| Fr | Scienture: Blutdrucksenker Arbli in drei US-Kinderkliniken gelistet | 1 | Investing.com Deutsch | ||
| Fr | Scienture's Arbli added to three pediatric hospital formularies | 1 | Investing.com | ||
| Fr | Scienture Holdings, Inc.: SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals | 1 | GlobeNewswire (USA) | ||
| Fr | EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions | 2 | Benzinga.com | ||
| Do | Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened | 2 | Benzinga.com | ||
| SCIENTURE Aktie jetzt für 0€ handeln | |||||
| Mi | Scienture Holdings to implement 1-for-25 reverse stock split | 1 | Investing.com | ||
| Mi | Scienture announces 1-for-25 reverse stock split | 2 | Seeking Alpha | ||
| Mi | Scienture Holdings, Inc. Announces Reverse Stock Split | 124 | GlobeNewswire (Europe) | COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing... ► Artikel lesen | |
| 22.09. | Scienture secures distribution deal for naloxone nasal spray | 4 | Investing.com | ||
| 22.09. | Scienture Holdings, Inc.: SCIENTURE Expands Commercial Reach of REZENOPY to Addiction Treatment Centers through an Agreement with a Distribution Partner | 2 | GlobeNewswire (USA) | ||
| 14.09. | Scienture Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | Scienture Holdings, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 14.08. | Scienture Holdings Q2 non-GAAP EPS of -$0.07, revenue of $0.34M | 1 | Seeking Alpha | ||
| 14.08. | Scienture Holdings, Inc.: SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance | 609 | GlobeNewswire (Europe) | Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million... ► Artikel lesen | |
| 13.08. | Scienture Holdings, Inc. - 10-Q, Quarterly Report | 12 | SEC Filings | ||
| 12.08. | Scienture Holdings, Inc.: SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY, the Highest Dose FDA-Approved Naloxone Nasal Spray | 9 | GlobeNewswire (USA) | ||
| 12.08. | EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US | 12 | Benzinga.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 40,270 | -0,33 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| ECKERT & ZIEGLER | 12,380 | +0,16 % | Eckert&Ziegler mit EILMELDUNG: Meine brandneue Prognose ändert einfach alles - Handeln Sie, bevor es zu spät ist! | ||
| INTUITIVE SURGICAL | 348,55 | +0,14 % | Can ISRG Offset China Weakness With Expansion in India and Japan? | ||
| UNITEDHEALTH | 332,40 | +0,61 % | UnitedHealthcare Unveils FY27 Medicare Advantage Plans | MINNETONKA (dpa-AFX) - Health care and well-being major UnitedHealth Group Inc. (UNH) Thursday introduced its 2027 Medicare Advantage plans, focused on affordability, simplicity and a more connected... ► Artikel lesen | |
| DRAEGERWERK | 117,00 | -1,52 % | Drägerwerk-Aktie // Dicker Freudensprung | Bei Drägerwerk läuft das Geschäft weiterhin sehr gut. Dies belegen überzeugende Zahlen für das erste Halbjahr. So erhöhte sich der Umsatz um 6,2 Prozent auf rund 1,6 Milliarden Euro. Bereinigt wäre... ► Artikel lesen | |
| MEDTRONIC | 76,72 | 0,00 % | Medtronic Announces Regulatory Milestones For Cardiac Mapping Software | WASHINGTON (dpa-AFX) - Wednesday, Medtronic plc (MDT) said it received FDA clearance and CE Mark for the latest Affera Prism-2 Mapping Software and CE Mark for the PulseSelect ProxBox Adapter... ► Artikel lesen | |
| THERMO FISHER | 581,60 | -0,03 % | Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno | Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflowsSINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| TELADOC HEALTH | 4,897 | -0,04 % | Teladoc Aktie setzt Talfahrt fort: Chefjurist geht, Sorgen bleiben | ||
| HIMS & HERS HEALTH | 25,960 | +0,78 % | Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership | Kultar Garcha, MD, joins as Chief Medical Officer of the UK and EMEA, and Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, is named Chief Medical Officer of Hims Australia, guiding clinical strategy... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,069 | +2,38 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| FAMICORD | 3,070 | +0,99 % | EQS-News: FamiCord AG gewinnt vielversprechenden CDMO-Neukunden mit Herstellungsvereinbarung für zulassungsrelevante Phase-II/III-Studie bei anfänglichem Volumen im niedrigen einstelligen Millionen-Euro-Bereich | EQS-News: FamiCord AG
/ Schlagwort(e): Vertrag
FamiCord AG gewinnt vielversprechenden CDMO-Neukunden mit Herstellungsvereinbarung für zulassungsrelevante Phase-II/III-Studie bei... ► Artikel lesen | |
| M1 KLINIKEN | 20,150 | +3,74 % | Drohnenauftrag für Volatus, KI-Strom treibt Infineon und Beauty-Boom bei M1 Kliniken: Drei spannende Aktien im Check | Drohnen fürs kanadische Militär, Chips für den KI-Boom und Schönheitsbehandlungen mit satten Margen: Börsenfantasie hat viele Gesichter. Volatus Aerospace könnte mit einem kanadischen Militärauftrag... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 38,110 | +0,73 % | Elutia Inc.: Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 | Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,110 | -1,81 % | Geratherm Medical Aktie: Der Umbau soll die Wende bringen | Geratherm Medical steckt operativ weiter in einer schwierigen Phase. Im ersten Halbjahr 2026 sank der Umsatz um 12,5 Prozent auf 7,0 Millionen Euro, während das EBIT auf minus 0,5 Millionen Euro zurückging.... ► Artikel lesen | |
| DEXCOM | 76,40 | +0,53 % | DexCom, Inc.: Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care | New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1 New partnership reinforces... ► Artikel lesen |